Patent ID: 11911469
Assignee: CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCIENCES
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 7:
8. The method of claim 1, wherein:
the ACAT1 inhibitor is avasimibe;
the immune checkpoint inhibitor is selected from the group consisting of pembrolizumab, nivolumab, J43, RMP1-14, atezolizumab, ipilimumab, and combinations thereof; and
the melanoma is selected from the group consisting of Lentigo maligna, Lentigo maligna melanoma, superficial spreading melanoma, acral lentiginous melanoma, mucosal melanoma, nodular melanoma, polypoid melanoma, desmoplastic melanoma, amelanotic melanoma, and soft-tissue melanoma.